Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs iShares Silver Trust — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while iShares Silver Trust trades at $51.18 (market cap $29.73B). The key difference: iShares Silver Trust is far larger — about 30.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and iShares Silver Trust for 90 Days on average.
| MRVI | SLV | |
|---|---|---|
Market Cap | $972.90M | $29.73B |
Volume | 4,325,710 | 17,545,887 |
Sector | Health | — |
52-Week High | $9.00 | $105.57 |
52-Week Low | $2.83 | $42.40 |
Typical Hold Time | 0 Days | 90 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
SLV, the iShares Silver Trust ETF, is trading at $50.22, down 7.6% over 24 hours amid a bearish technical signal. The trust holds substantial assets of $13.41 billion with minimal liabilities, but financial metrics like P/E and revenue are unavailable. Recent news highlights pressure from rising Treasury yields and a stronger dollar, contributing to silver's sharp decline.
The outlook remains cautious due to macroeconomic headwinds and Fed policy uncertainty. While silver's industrial and monetary appeal offers long-term potential, near-term volatility and bearish technical indicators suggest limited upside. Risks include interest rate sensitivity and market sentiment shifts, requiring careful monitoring for entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
